Drug research

PRO 140

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Humanized monoclonal antibody to CCR5; Leronlimab

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
PRO 140 in Treatment-Experienced HIV-1 SubjectsNCT03902522	CytoDyn, Inc.	Phase 2, Phase 3	Completed	2020-05-18Actual
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyNCT02990858	CytoDyn, Inc.	Phase 2, Phase 3	Terminated	2022-06Actual
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell TransplantationNCT02737306	CytoDyn, Inc.	Phase 2	Terminated	2021-04-14Actual

CytoDyn, Inc.CompletedPrimary completion: 2020-05-18 · Actual

Trial details

CytoDyn, Inc.TerminatedPrimary completion: 2022-06 · Actual

Trial details

CytoDyn, Inc.TerminatedPrimary completion: 2021-04-14 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.